Elixion is a biotechnology company developing novel therapeutics through a unique R&D approach that combines quantum physics, causal biology, multi-omics and native AI.
Our mission is to bring discoveries faster to those who need them most, patients. We achieve this by working closely with experienced medical advisors to ensure that every programme we advance addresses real-world unmet needs medically, clinically, and holistically.
We believe great science only makes an impact when matched with strong execution. Our senior leadership brings together expertise in systems biology, machine learning, clinical R&D, legal, strategy, and venture development – a mix that ensures we can deliver.
Our long-term focus is clear: building scalable R&D, moving rapidly from lab to market, and delivering measurable clinical and commercial success.
“Elixion was born from a shared belief that scientific excellence must translate into real-world therapies. We are here to build that bridge.” Marco Piccinini, Co-Founder and CEO
Our guiding principles
